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GENOTYPING OF HUMAN CYTOMEGALOVIRUS (HCMV) GLYCOPROTEIN
B (GB) IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
WITH ACTIVE HCMV INFECTION: IMPACT OF gB GENOTYPES ON THE
PATIENT’S OUTCOME
Dieamant, D.C., Bonon, S.H.A., Murakami, M.M., Aranha, F.J.P.,
Duarte, G.O., Fernandes, V.C.A., de Souza, C., Costa, S.C.B.,
Vigorito, A.C. State University of Campinas, Campinas, Sao Paulo, Brazil
Based on sequence variation in the UL55 gene that encodes glyco-
protein B (gB), human cytomegalovirus (HCMV) can be classified
into four gB genotypes. There is little information about the CMV
gB genotype and clinical outcome in patients who underwent an
allogeneic hematopoietic stem cell transplant (HSCT) in Brazil.
Objectives:The goal of this study was to determine the distribution
of gB genotypes in allogeneic HSCT patients with CMV infection
and the effect of gB type on clinical outcome includingCMVdisease.
Study design: The diagnosis of HCMV infection after allogeneic
HSCT was detected by Antigenemia (AGM) and Nested-PCR (N-
PCR). All patients withCMV infection received ganciclovir preemp-
tive treatment. Positive samples from patients with activeHCMV in-
fection were submitted to genotyping using the N-PCR to amplify
a region of UL55, followed by restriction analysis based on HinfI
and RsaI digestion and subsequent sequencing aligned with known
CMV variants in GenBank.
Results:Were evaluated 55 allogeneic HSCT recipients, 41/55 pa-
tients (74,5%) presented active HCMV infection detected by AGM
and/or N-PCR, a median time of 32 days after the transplant. The
distribution of HCMV gB genotypes in 30/41 patients with
HCMV active infection was as follow: gB1, 14/30 (46,6%); gB2,
10/30 (33,3%); gB3, 2/30 (6,7%); gB4, 2/30 (6,7%) and two patients
(6,7%) had mixed infection whit gB1+gB3 and gB2+gB3. The se-
quencing confirmed the four CMV gB genotypes. HCMV disease
developed in 2 patients, characterized for gastrointestinal disease
and these two patients had infection with a mixture of HCMV gB
genotypes.
Conclusions: in this study the most prevalent genotype in patients
with HCMV active infection was gB type1 and moreover, the
mixture of HCMV gB genotypes was associate with gastrointestinal
disease. It suggests that gB genotypes may have influence on the
patient’s outcome in a Brazilian population.
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RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (SCT):
RETRANSPLANTATION DOES NOT IMPROVE OUTCOME IN COMPARISON
TO SUPPORTIVE CARE AND CHEMOTHERAPY
Arnold, R., Hemmati, P., Terwey, T., Voung, L., le Coutre, P.,
Doerken, B., Massenkeil, G. Charite University Medicine Berlin, Berlin,
Germany
Relapse post allogeneic SCT is a life threatening event and we re-
port here our treatment strategies.
Between 12/1994 and 6/2010 449 pts. (median age: 42 years, 16 –
70) underwent allogeneic SCT from an unrelated (n 5 263) or
a matched related (n5 186) donor for treatment of acute myeloblas-
tic leukemia, AML (n 5 277) or acute lymphocytic leukemia, ALL
(n 5 172). 240 pts. were transplanted in CR1, 209 pts. beyond
CR1. 241 pts. were male, 208 pts. were female. Post allogeneic
SCT 193/449 pts. (43 %) are alive in complete remission (CR),
142/449 pts. (32 %) relapsed and 114/449 pts. (25 %) died due to
non relapse mortality (NRM). In the 142 relapsed patients the me-
dian duration of remission post allogeneic SCTwas short (5 months,
1 – 135) and themedian age of the patients at relapse was 43 years (17
– 68). Our treatment strategies for relapse were as follows: Firstly
stop of immunosuppression. Thereafter, in fit patients reinduction
chemotherapy followed by 2nd allogeneic SCT was given. Patients
with contraindications received supportive care 6 chemotherapy
or chemotherapy and DLI. 30/142 pts. underwent 2nd allogeneic
SCT for treatment of relapse (same donor n9, other donor n21)
and 112/142 pts. received conventional therapy.
Results: 2/30 pts. (7 %) are alive at 9 and 16 months after 2nd allo-
geneic SCT and 28/30 pts. died at a median of 3 months (0 – 15) post
2nd SCT. Causes of death are leukemia in 21/28 pts. (75 %) at a me-
dian of 4 months (1 – 13) post 2nd SCT. 7/28 pts. (25 %) died due to
NRM (gvhd, infection, toxicity) at a median of 1 month (0 – 15) after2nd SCT. The time interval between relapse and 2nd SCTwas in me-
dian 4months (1 – 56). Survival after 1st relapse in the Re-SCTgroup
was 10 months (3 – 69 months). With conventional therapy 7/112
pts. (6 %) are alive with a median follow-up of 17 months (2 – 50)
after relapse and 105/112 pts. are dead. Causes of death are leukemia
in 104/105 pts., 2nd malignancy in 1/105. Median survival after 1st
relapse and conventional therapy is 2 months (0.1 – 50 months). In
Conclusion: Prognosis of relapse after allogeneic SCT is dismal.
The longer survival of the Re-SCT group in comparison to the con-
ventional group might reflect a selection of better risk patients. Pro-
spective studies are needed to identify patients who will benefit from
a 2nd SCT as compared to non-transplant treatment.
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THE TIMING OF ALEMTUZUMAB SIGNIFICANTLY IMPACTS MIXED CHI-
MERISM AND ACUTE GRAFT VERSUS HOST DISEASE
Marsh, R.A.1, Li, D.2, Kim, M.-O.2, Hart, L.1, Joshi, S.1, Jodele, S.1,
Mehta, P.1, Jordan, M.B.1, Bleesing, J.J.1, Davies, S.M.1,
Filipovich, A.H.1 1Cincinnati Children’s Hospital Medical Center, Cin-
cinnati, OH; 2Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH
Reduced-intensity conditioning (RIC) regimens that contain
alemtuzumab are often associated with a high incidence of mixed
chimerism and a low incidence of acute graft versus host disease
(GVHD). Both observations may be due to alemtuzumab-mediated
depletion of graft lymphocytes. To determine if the timing of alem-
tuzumab administration affects the incidences of mixed chimerism
and acute GVHD, we compared the outcomes of 102 patients with
non-malignant diseases who underwent RIC-HCT using fludara-
bine and melphalan at our institution with 2 different alemtuzumab
schedules. Forty-nine patients received a proximal alemtuzumab
schedule, consisting of a median dose of 1mg/kg alemtuzumab di-
vided over 4-5 consecutive days between days -12 to -4. Fifty-two pa-
tients received a distal alemtuzumab schedule, consisting of a median
dose of 2.6mg/kg alemtuzumab divided over 3-4 consecutive days
between days -23 to -19. All patients engrafted at a median of 11.5
days with the exception of 1 patient in each group who died at
days +7 and +15. Excluding these 2 patients, the overall incidence
of acute rejection and/or mixed chimerism in the proximal group
(2 patients with acute rejection) was 35/48 patients (73%) versus
20/51 patients (39%) in the distal group (no acute rejection) (p 5
0.01). Acute GVHD prophylaxis was rapidly weaned in the majority
of patients with mixed chimerism. Six patients in the proximal group
and 4 patients in the distal group received hematopoietic cell boost (p
5 0.16), and donor lymphocyte infusions (DLI) were administered
to 18 patients in the proximal group and 5 patients in the distal group
(p5 0.002). Prior to these interventions, acute GVHD grades II-IV
developed in only 1 patient in the proximal group (2%), and 9 pa-
tients in the distal group (17%) (p5 0.05). Following these interven-
tions, acute GVHD grades II-IV occurred in 7 patients in the
proximal group and 6 patients in the distal group, making the total
overall incidence of acute GVHD grades II-IV 16% in the proximal
group versus 29% in the distal group (p5 0.1). Ultimately, 4 patients
in the proximal group and 1 patient in the distal group required a sec-
ond transplant. We conclude that the timing of alemtuzumab signif-
icantly influences the incidences of both mixed chimerism and acute
GVHD. Further studies to optimize the dosing schedule of alemtu-
zumab are warranted.
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NOTGETTING HIGH ON BUSULFAN: A NOVEL APPROACH TO AVOID HIGH
BUSULFAN LEVELS IN ADULTS AND CHILDREN UNDERGOING HSCT
Shaw, P.J.1, Ritchie, D.S.2, Gibson, J.3, Larsen, S.R.3, Grigg, A.2,4,
Hertzberg,M.5, Fay, K.6, Nath, C.E.1 1Children’s Hospital at Westmead,
Sydney, NSW, Australia; 2Royal Melbourne Hospital, Parkville, VIC,
Australia; 3Royal Prince Alfred Hospital, Sydney, NSW, Australia; 4Aus-
tin Hospital, VIC, Australia; 5Westmead Hospital, Westmead, NSW,
Australia; 6Royal North Shore Hospital, Sydney, NSW, Australia
Background:Work based on oral Busulfan (Bu) suggests low levels
may be associated with rejection and high levels with toxicity. Data
with IV Bu is sparse but generally in keeping with this. High Bu ex-
posure (AUC . 6000mM.min) has been associated with worse out-
come in adults given BuFlu or BuCy and in children after a variety
